Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.

NMN is considered safe to use with dutasteride, and it may help reduce grey hairs. Combining NMN with creatine, whey protein, fish oil, and dutasteride is not seen as excessive.

The conversation discusses the pros and cons of using propylene glycol versus ethyl alcohol in topical solutions for finasteride and minoxidil. It questions why propylene glycol is commonly used and whether ethyl alcohol might be a better option.

Pyrilutamide is considered to work for hair loss but less effectively than expected, similar to RU58841, and may cause side effects like chest tightness and sexual issues. It's unclear if it's suitable for diffuse thinners, and one user cannot use minoxidil or finasteride due to side effects and personal circumstances.

The user is seeking advice on effectively applying a liposomal solution of Minoxidil and Finasteride for hair loss, specifically targeting the roots without wasting the product. They find it challenging to use only 1 ml to cover thinning areas on the front and crown.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

Aminexil is similar to Minoxidil but less effective and not widely used, with some users reporting minor regrowth. It is not FDA-approved and has been removed from some products, though some people still use it, often in combination with Minoxidil.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user is considering combining 1mg oral finasteride with 0.1% topical finasteride due to reduced effectiveness after 5 years and is also using minoxidil twice daily. They previously tried dutasteride but stopped due to side effects and are hesitant to try RU58841.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

Creatine use with finasteride increased DHT levels, possibly affecting hair loss. The user plans to reduce creatine to stabilize DHT and hair shedding.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

The conversation is about whether dissolving finasteride in water affects its effectiveness. The user is concerned about the impact of water on the medication's efficacy over five days.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

A user is considering dutasteride mesotherapy for hair loss due to concerns about oral side effects from high DHT levels. They have been using topical finasteride with minoxidil but are exploring mesotherapy as an alternative, while another user shares their experience with mesotherapy sessions using dutasteride and minoxidil without side effects.

Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.